Literature DB >> 20166957

Phosphodiesterase inhibitors as potential cognition enhancing agents.

Christopher J Schmidt1.   

Abstract

As might be predicted for an organ designed for cell to cell communication, cyclic nucleotide signaling in the brain is highly organized and regulated. Augmentation of cyclic nucleotide signaling by means of phosphodiesterase inhibition appears to be a viable and tractable means of enhancing neuronal communication. Of the various CNS disorders that have been considered as target indications for phosphodiesterase inhibitors, no condition has received more attention than cognitive dysfunction. This review provides a background for understanding the expanding literature in this field as well as a brief update on the rationale driving the search for selective inhibitors of targets such as PDE1B, PDE2, PDE5 and PDE9.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20166957     DOI: 10.2174/156802610790411009

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  15 in total

Review 1.  Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness.

Authors:  Dan Li; David J Paterson
Journal:  J Physiol       Date:  2016-05-05       Impact factor: 5.182

2.  The Phosphodiesterase 9 Inhibitor PF-04449613 Promotes Dendritic Spine Formation and Performance Improvement after Motor Learning.

Authors:  Baoling Lai; Miao Li; Wanling Hu; Wei Li; Wen-Biao Gan
Journal:  Dev Neurobiol       Date:  2018-07-18       Impact factor: 3.964

3.  Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.

Authors:  Frederik J R Rombouts; Gary Tresadern; Peter Buijnsters; Xavier Langlois; Fulgencio Tovar; Thomas B Steinbrecher; Greet Vanhoof; Marijke Somers; José-Ignacio Andrés; Andrés A Trabanco
Journal:  ACS Med Chem Lett       Date:  2015-01-15       Impact factor: 4.345

Review 4.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

Review 5.  Phosphodiesterases and cardiac cGMP: evolving roles and controversies.

Authors:  Manling Zhang; David A Kass
Journal:  Trends Pharmacol Sci       Date:  2011-04-07       Impact factor: 14.819

6.  Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.

Authors:  Y S Shim; C-U Pae; K J Cho; S W Kim; J C Kim; J S Koh
Journal:  Int J Impot Res       Date:  2013-11-28       Impact factor: 2.896

7.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors:  John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

8.  The distribution of phosphodiesterase 2A in the rat brain.

Authors:  D T Stephenson; T M Coskran; M P Kelly; R J Kleiman; D Morton; S M O'Neill; C J Schmidt; R J Weinberg; F S Menniti
Journal:  Neuroscience       Date:  2012-09-19       Impact factor: 3.590

Review 9.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

Review 10.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.